A 3-month, randomized, double-blind, placebo-controlled, multicenter, safety, tolerability, and efficacy study of 3 doses of lecozotan (SRA-333) SR [sustained release] in outpatients with mild to moderate Alzheimer's disease with donepezil as active control
Latest Information Update: 18 May 2022
At a glance
- Drugs Donepezil (Primary) ; Lecozotan (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- 19 Jul 2012 Results presented in combination with results from the 203 study at the 2012 International Conference on Alzheimer's Disease.
- 19 Jul 2012 Patient numbers changed from 229 to 372 as reported in the conference abstract
- 03 Jul 2012 Eisai and Pfizer added as associations as reported in the European Clinical Trials Database record.